Intuitive Surgical (NASDAQ:ISRG) Given New $570.00 Price Target at Truist Financial

Intuitive Surgical (NASDAQ:ISRG) had its price objective increased by Truist Financial from $520.00 to $570.00 in a research report sent to investors on Monday morning, Benzinga reports. Truist Financial currently has a buy rating on the medical equipment provider’s stock.

Several other equities research analysts have also recently issued reports on ISRG. Robert W. Baird raised their target price on Intuitive Surgical from $487.00 to $503.00 and gave the stock an “outperform” rating in a research note on Friday, July 19th. JPMorgan Chase & Co. increased their price target on Intuitive Surgical from $495.00 to $575.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Evercore ISI boosted their price objective on shares of Intuitive Surgical from $410.00 to $475.00 and gave the company an “in-line” rating in a report on Tuesday, October 1st. Redburn Atlantic raised shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and upped their target price for the company from $380.00 to $510.00 in a research report on Friday, August 2nd. Finally, Morgan Stanley lifted their price target on shares of Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a research report on Monday, July 15th. Six equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and a consensus price target of $484.15.

Intuitive Surgical Trading Down 0.6 %

Shares of ISRG stock opened at $473.73 on Monday. Intuitive Surgical has a twelve month low of $254.85 and a twelve month high of $496.48. The company’s 50-day moving average price is $482.69 and its 200-day moving average price is $436.91. The stock has a market cap of $168.03 billion, a price-to-earnings ratio of 85.51, a PEG ratio of 5.40 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.24. The company had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. Intuitive Surgical’s revenue was up 14.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.18 EPS. As a group, equities research analysts predict that Intuitive Surgical will post 5.22 EPS for the current year.

Insider Buying and Selling

In other news, insider Mark Brosius sold 2,115 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $491.91, for a total transaction of $1,040,389.65. Following the completion of the transaction, the insider now directly owns 295 shares of the company’s stock, valued at approximately $145,113.45. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, insider Mark Brosius sold 2,115 shares of Intuitive Surgical stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $491.91, for a total transaction of $1,040,389.65. Following the completion of the sale, the insider now directly owns 295 shares of the company’s stock, valued at approximately $145,113.45. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Robert Desantis sold 1,413 shares of the business’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $438.60, for a total transaction of $619,741.80. Following the transaction, the executive vice president now owns 5,506 shares of the company’s stock, valued at approximately $2,414,931.60. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 53,120 shares of company stock valued at $25,528,753 in the last three months. 0.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Intuitive Surgical

Hedge funds and other institutional investors have recently made changes to their positions in the business. Capital Research Global Investors purchased a new stake in Intuitive Surgical in the first quarter valued at $374,390,000. Vanguard Group Inc. lifted its holdings in shares of Intuitive Surgical by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock valued at $12,319,358,000 after purchasing an additional 493,126 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in shares of Intuitive Surgical by 51.2% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 893,341 shares of the medical equipment provider’s stock valued at $356,524,000 after purchasing an additional 302,382 shares during the last quarter. Strategic Financial Concepts LLC boosted its position in shares of Intuitive Surgical by 40,221.4% in the 2nd quarter. Strategic Financial Concepts LLC now owns 266,121 shares of the medical equipment provider’s stock valued at $1,184,000 after purchasing an additional 265,461 shares during the period. Finally, GQG Partners LLC purchased a new position in Intuitive Surgical during the 1st quarter worth approximately $99,523,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.